Skip to main content

13-09-2022 | ESMO 2022 | Conference coverage | Video

COSMIC-313 points to first-line triplet option for advanced RCC

share
SHARE

Toni Choueiri tells us about the COSMIC-313 trial evaluating the addition of cabozantinib to nivolumab plus ipilimumab in intermediate- or poor-risk patients with treatment-naïve, advanced renal cell carcinoma (2:53).